ADX-629

ADX-629 · Aldeyra Therapeutics, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ADX-629, covering 2025-02-28 to 2026-02-10. Get the full timeline:

Most recent: Clinical Trial Update: ADX-629 Therapy for Sjogren-Larsson Syndrome [Phase 1, Phase 2]